AU2002228922A1 - Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof - Google Patents
Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereofInfo
- Publication number
- AU2002228922A1 AU2002228922A1 AU2002228922A AU2892202A AU2002228922A1 AU 2002228922 A1 AU2002228922 A1 AU 2002228922A1 AU 2002228922 A AU2002228922 A AU 2002228922A AU 2892202 A AU2892202 A AU 2892202A AU 2002228922 A1 AU2002228922 A1 AU 2002228922A1
- Authority
- AU
- Australia
- Prior art keywords
- arylaminopyrimidines
- caspases
- inducers
- activators
- apoptosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000011727 Caspases Human genes 0.000 title 1
- 108010076667 Caspases Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 239000000411 inducer Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25458100P | 2000-12-12 | 2000-12-12 | |
| US60254581 | 2000-12-12 | ||
| PCT/US2001/047498 WO2002047690A1 (en) | 2000-12-12 | 2001-12-12 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002228922A1 true AU2002228922A1 (en) | 2002-06-24 |
Family
ID=22964830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002228922A Abandoned AU2002228922A1 (en) | 2000-12-12 | 2001-12-12 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1351691A4 (en) |
| AU (1) | AU2002228922A1 (en) |
| WO (1) | WO2002047690A1 (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154747A0 (en) | 2000-09-15 | 2003-10-31 | Vertex Pharma | Pyrazole derivatives and pharmaceutical compositions containing the same |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6716851B2 (en) | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| CA2432303C (en) | 2000-12-21 | 2010-04-13 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| AU2003256783A1 (en) * | 2002-07-25 | 2004-02-16 | Scios, Inc. | METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS |
| DK1532145T3 (en) | 2002-08-02 | 2007-01-15 | Vertex Pharma | Pyrazole preparations useful as inhibitors of GSK-3 |
| CA2439440A1 (en) | 2002-09-05 | 2004-03-05 | Emory University | Treatment of tuberous sclerosis associated neoplasms |
| JP2006503043A (en) * | 2002-09-10 | 2006-01-26 | サイオス インク． | TGFβ inhibitor |
| US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| CA2520323C (en) * | 2003-04-09 | 2013-07-09 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| CN1984660B (en) | 2003-07-03 | 2010-12-15 | 美瑞德生物工程公司 | 4-arylamino-quinazolines as activators of aspartic acid specificity cysteine protease and inducers of apoptosis |
| EP1656372B1 (en) | 2003-07-30 | 2013-04-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| US6818631B1 (en) | 2003-08-15 | 2004-11-16 | Nippon Soda Co. Ltd. | Fungicidal pyrimidine derivatives |
| EP1678146A1 (en) * | 2003-10-23 | 2006-07-12 | Pharmacia Corporation | Pyrimidine compounds for the treatment of inflammation |
| US8455489B2 (en) | 2003-11-10 | 2013-06-04 | Exelixis, Inc. | Substituted pyrimidine compositions and methods of use |
| PT1689715E (en) | 2003-12-03 | 2011-05-16 | Ym Biosciences Australia Pty | Tubulin inhibitors |
| WO2005058883A1 (en) * | 2003-12-15 | 2005-06-30 | Almirall Prodesfarma Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| US7560464B2 (en) | 2004-04-13 | 2009-07-14 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
| JP4602686B2 (en) * | 2004-04-15 | 2010-12-22 | 広栄化学工業株式会社 | Process for producing 2,6-dihalogeno-4-arylpyridines |
| JP4990766B2 (en) * | 2004-07-01 | 2012-08-01 | シンタ ファーマシューティカルズ コーポレーション | Disubstituted heteroaryl compounds |
| ATE485822T1 (en) | 2004-09-06 | 2010-11-15 | Basilea Pharmaceutica Ag | PHENYLAMINOPYRIDINES AND PHENYLAMINOPYRAZINE |
| AU2005286592A1 (en) | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| KR20070107061A (en) * | 2005-01-25 | 2007-11-06 | 아스트라제네카 아베 | Chemical compounds |
| ATE502936T1 (en) * | 2005-04-11 | 2011-04-15 | Almirall Sa | 2, 6-DI-(HETERO-)ARYL-4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS |
| GB0520657D0 (en) * | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| US7713987B2 (en) | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
| EP1878733A1 (en) * | 2006-07-14 | 2008-01-16 | Novartis AG | Pyrimidine derivatives as ALK-5 inhibitors |
| JP4960450B2 (en) | 2006-07-14 | 2012-06-27 | ノバルティス アーゲー | Pyrimidine derivatives as ALK-5 inhibitors |
| JP2010502674A (en) * | 2006-09-07 | 2010-01-28 | ノイロサーチ アクティーゼルスカブ | Pyridinyl-pyrimidine derivatives useful as potassium channel modulators |
| EP2222162B1 (en) | 2007-11-28 | 2016-11-16 | Dana-Farber Cancer Institute, Inc. | Small molecule myristate inhibitors of bcr-abl and methods of use |
| BR112013013898B1 (en) * | 2010-12-06 | 2021-10-13 | Glaxo Group Limited | PYRIMIDINONE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING SUCH COMPOUNDS AND USE OF THEM FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ATHEROSCLEROSIS |
| WO2012075917A1 (en) * | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Compounds |
| JP6116554B2 (en) * | 2011-07-07 | 2017-04-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Substituted azaheterocycles for the treatment of cancer |
| JP2014237590A (en) * | 2011-09-30 | 2014-12-18 | アステラス製薬株式会社 | 2-(pyridine-2-yl) pyrimidine-4-amine compound or a salt thereof |
| EP2847180B1 (en) * | 2012-05-11 | 2017-01-04 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| WO2014015936A1 (en) * | 2012-07-23 | 2014-01-30 | Merck Patent Gmbh | Ligands and their preparation |
| CN102887860B (en) * | 2012-09-29 | 2015-07-01 | 上海泰坦科技有限公司 | Preparation method of 4-chloro-6-trifluoromethylpyrimidine type compound |
| CN111423417B (en) * | 2012-11-21 | 2022-11-15 | Ptc医疗公司 | Substituted reverse pyrimidine Bmi-1 inhibitors |
| CN103896856B (en) * | 2012-12-25 | 2016-06-08 | 叶龙 | A kind of polysubstituted monocycle miazines JNK kinase inhibitor and its production and use |
| CN108976172B (en) * | 2017-05-31 | 2021-12-07 | 华东师范大学 | 4-pyrimidinediamine micromolecule organic compound and derivative and application thereof |
| CN108715589B (en) * | 2018-06-19 | 2021-04-20 | 华侨大学 | Coumarin derivative used as caspase-3 activator and application thereof |
| EP3836932A2 (en) | 2018-08-17 | 2021-06-23 | PTC Therapeutics, Inc. | Method for treating pancreatic cancer |
| BR112021007679A2 (en) | 2018-10-22 | 2021-07-27 | Esker Therapeutics, Inc | tyk2 inhibitors and their uses |
| US20220143016A1 (en) * | 2019-02-28 | 2022-05-12 | Ptc Therapeutics, Inc. | Method for treating a multiple myeloma |
| CN114096537A (en) * | 2019-03-27 | 2022-02-25 | Ptc医疗公司 | Useful combinations of sarcoma treatment methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4041030A (en) * | 1973-09-20 | 1977-08-09 | Delalande S.A. | Arylamino pyrimidinic derivatives |
| EP0629622B1 (en) * | 1992-02-28 | 1998-11-11 | Zenyaku Kogyo Kabushikikaisha | S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient |
| EP0640599B1 (en) * | 1993-08-26 | 1998-03-04 | Ono Pharmaceutical Co., Ltd. | 4-Aminopyrimidine derivatives |
| AU7508594A (en) * | 1993-09-01 | 1995-03-22 | Nippon Kayaku Kabushiki Kaisha | Medical use of polysulfonic acid compound |
| US5935966A (en) * | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| CA2230894A1 (en) * | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
| EP0994860A1 (en) * | 1997-07-03 | 2000-04-26 | Du Pont Pharmaceuticals Company | Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
-
2001
- 2001-12-12 AU AU2002228922A patent/AU2002228922A1/en not_active Abandoned
- 2001-12-12 WO PCT/US2001/047498 patent/WO2002047690A1/en not_active Application Discontinuation
- 2001-12-12 EP EP01990048A patent/EP1351691A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002047690A1 (en) | 2002-06-20 |
| EP1351691A1 (en) | 2003-10-15 |
| EP1351691A4 (en) | 2005-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002228922A1 (en) | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
| EP1406632A4 (en) | Substituted 3-aryl-5-aryl- 1,2,4 -oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
| AU2004253967A8 (en) | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis | |
| IL184144A0 (en) | Intermediates useful in the preparaiton of 2-aminocarbonyl-9h-purine derivatives | |
| AU2003241482A1 (en) | Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
| AU2002213467A8 (en) | Modulation of ccr4 function | |
| AU2001282449A8 (en) | Applications of the biofeedback technique | |
| HK1078088A1 (en) | Substituted phenylacetamides and their use as glucokinase activators | |
| IL162266A (en) | Substituted 2-thio-3,5-dicyano-4- phenyl-6-aminopyridines and the use of the same | |
| AU5227001A (en) | Hydantoin-containing glucokinase activators | |
| AU2001293372A1 (en) | Substituted 1,4-thiazepine and analogs and their use as activators of caspases | |
| AU2002219135A1 (en) | Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors | |
| AU2002303694A1 (en) | Substituted n'-(arylcarbonyl)-benzhydrazides, n'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
| AU2001292732A1 (en) | Beta-lactam analogs and uses therefor | |
| EP1404329A4 (en) | Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
| EP1578424A4 (en) | Substituted 1-benzoyl-3-cyano-pyrrolo 1,2-a| quinolines and analogs as activators of caspases and inducers of apoptosis | |
| EP1509515A4 (en) | Substituted 4-aryl-4h-pyrrolo 2,3-h chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
| PL361733A1 (en) | Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors | |
| AU2001293048A1 (en) | Antiviral compositions and methods of use | |
| EP1399159A4 (en) | 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
| AU2001271426A1 (en) | Modulation of apoptosis | |
| EP1392294A4 (en) | 7,8-fused 4$i(h)-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
| AU2001247966A1 (en) | Bioactive fraction of eurycoma longifolia | |
| AU2001252627A1 (en) | Polybenzasol fiber and use of the same | |
| AU2185199A (en) | Apoptosis inducers |